Korea Quality Re-Rating Watch 2026-06-29: Gigavis, Mirae Industry & VM — KOSDAQ Sidecar Day, Institutional Bid Stays Selective

Macro Dashboard

Regime: Korea — Bear | US — Neutral

Market breadth remains the defining constraint: only 12.6% of Korean stocks trade above their 50-day moving average, and 22.3% above their 200-day. Week-level index gains are real but narrow. Program selling hit ₩4.8 trillion today; ETF net creation of ₩2.9 trillion provided partial cushion. Futures basis of +13.96 signals no acute stress, but the Korea Bear / US Neutral divergence keeps the tactical stance defensive.

Market Wrap

Today’s Korea session split cleanly in two. KOSPI fell -0.20% to 8,394.65 as Samsung Electronics (005930.KS) dropped -4.9% and SK Hynix (000660.KS) declined -1.7%, both hit by synchronized foreign and program selling. The two names combined absorbed roughly ₩7.2 trillion in five-day foreign outflows. Institutions stepped in as partial buyers but could not absorb the scale.

KOSDAQ told the opposite story, surging +7.04% to 911.32 — a move large enough to trigger a buy-side sidecar. Biotech, secondary battery, and smaller growth stocks drove the move. 한올바이오파마 (009420.KS) was the headline momentum name, up +19.4% on the day and +39.3% over five sessions. The character of the KOSDAQ rally looks like sector rotation — money rotating away from KOSPI large-cap semiconductors — rather than a new fundamental catalyst opening up. Breadth across the KOSDAQ was better than the KOSPI, but this is a low bar given the narrow state of the overall market.

The macro backdrop adds a layer of structural support for the semiconductor thesis even as the day’s price action was negative for the sector’s largest names. Korea’s government reiterated a plan to invest ₩800 trillion in a southwest memory fabrication complex, ₩81 trillion in HBM packaging capacity in the Chungcheong region, and over ₩1,000 trillion in AI datacenter build-out through 2035. These numbers anchor the long-horizon case for memory and AI supply-chain companies. They do not, however, resolve the near-term foreign selling pressure in Samsung Electronics and SK Hynix.

Also circulating in today’s flow: DRAM supply-reduction and HBM transition-related legal noise. The signals are not indicative of confirmed litigation or earnings damage — they read as the kind of regulatory overhang that tends to appear when a cycle is running hot. Worth noting; not thesis-level.

One clean takeaway from today: this is a selective market, not a broad one. KOSDAQ’s +7% sidecar is a rotation signal. The semiconductor thesis is intact structurally; the short-term flow is complicated.

Today’s Quality Re-Rating Candidates

The KR Meta Screener ranked 83 tickers today. The framework prioritizes names appearing in two or more screeners simultaneously, with the strongest signal coming from the Quality Compounder + Smart Money Quality combination and the Quality Compounder + Cycle Rerating pairing.

Top Overlap Candidates

Top 3 Candidates in Detail

#1 — 기가비스 (420770.KQ) | Meta Score 75.4 | Five Screeners

Gigavis makes optical inspection equipment used inside semiconductor and display manufacturing lines. It is the only name today to clear five screeners simultaneously — Quality Compounder, Cycle Rerating, PEAD, Consensus Up Revision, and the Kiwoom Market Surface overlay. The earnings signal behind this is unusually sharp: operating profit grew +777% year-over-year, revenue +101%, and operating margin expanded +29.9 percentage points. The PEAD module gives it a Tier A score of +1.56, meaning the post-earnings drift signal has not yet been fully absorbed into price. Today’s close was ₩175,500, with a five-day gain of +10.2%. The Meta Screener places it first on score strength, which overrides the raw overlap ranking. Key risk to verify: the PER of 136x is pricing in substantial continued growth, and foreign net buying needs to confirm after today’s broader market selling.

#2 — 미래산업 (025560.KQ) | Meta Score 71.4 | Three Screeners

Mirae Industry manufactures semiconductor handler and test-related precision equipment. Today it is the only stock in the entire 2,712-name Korean universe to simultaneously clear both the Smart Money Quality screener and the Smart Money Earnings screener — the tightest filters in the framework. RS percentile is 97.1. The five-day institutional and foreign net buying of ₩2.1 billion, occurring while retail was net selling ₩2.6 billion, is exactly the kind of flow divergence this screen targets. A DART supply contract filing (단일판매·공급계약체결) on June 23 adds a concrete catalyst to the quality + flow combination. Revenue grew +88.1% year-over-year; operating profit declined -24.8%, a compression flag to watch. Short interest at 5.3% is a caution but not a disqualifier. Next check: whether the supply contract is material enough to drive consensus revisions higher.

#3 — 브이엠 (089970.KQ) | Meta Score 52.8 | Two Screeners

VM Co. makes CVD and deposition process equipment for the semiconductor industry. ROE is 14.8%, operating margin expanded +29.3 percentage points, and operating profit grew +387% year-over-year. Both Quality Compounder and Cycle Rerating screens confirm it. The caution is direct: foreign and quality-institutional investors net sold ₩38.4 billion over five days, with retail providing only partial offset. A June 23 DART supply contract filing suggests the order cycle is active. This is a name where the business fundamentals are re-rating clearly, but institutional money flow has not yet turned positive. Monitor for flow confirmation before treating it as a strong entry candidate.

A note on screener scarcity today: The Smart Money screens were extraordinarily tight — one pass each out of 2,712 stocks for both Smart Money Quality and Smart Money Earnings. Both passes were the same name: 미래산업 (025560.KQ). In an environment where breadth is at 12.6% above the 50-day moving average, that level of filter selectivity makes the double-pass a meaningful signal, not noise.

All data sourced from KR Meta Screener, KR Close Briefing, and Macro Regime outputs dated 2026-06-29. Market analysis only — not investment advice.